[肥胖中的肠道微生物组:个性化医学的新视野]
A V Starodubova1,2, O A Kislyak2, T Y Demidova2
1Federal Research Centre of Nutrition, Biotechnology and Food Safety.
Terapevticheskii arkhiv
|March 9, 2026
概括
肠道微生物组的改变与肥胖和代谢障碍有关. 本综述探讨了失生症机制,微生物群-肠-大脑轴,以及管理与肥胖有关的疾病的个性化策略.
科学领域:
- 微生物学 微生物学
- 代谢科学 代谢科学
- 胃肠病学 胃肠病学
背景情况:
- 肠道微生物群的干扰是导致肥胖和代谢障碍的关键因素.
- 了解肠道微生物组的组成和活性对于代谢健康至关重要.
研究的目的:
- 审查肥胖症中微生物群的特征和变异性.
- 讨论将肠道失调与代谢障碍联系在一起的机制.
- 介绍肥胖中微生物组相关疾病的诊断和治疗策略.
主要方法:
- 关于肥胖的肠道微生物群研究的文献综述.
- 分析机制,包括短链脂肪酸的产生,脂多糖诱导的炎症,以及微生物群-肠-大脑轴.
- 检查当前的诊断方法和个性化治疗策略.
主要成果:
- 肥胖与肠道微生物组成和代谢活动的特定变化有关.
- 失生症通过改变代谢物产量和慢性炎症导致代谢障碍.
- 微生物群-肠-大脑轴影响食欲和饮食行为.
结论:
- 肠道失生症在肥胖和相关代谢障碍的发病过程中起着重要作用.
- 针对肠道微生物组的个性化医疗方法为肥胖提供了潜在的治疗策略.
- 需要进一步的研究,以充分阐明肠道微生物群中的复杂相互作用及其对代谢健康的影响.
相关概念视频
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
336
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
336
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
259
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
259
Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Anatomy of the Intestines
89.0K
Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
89.0K
Drug Dosing: Obese Patients
321
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
321
Pharmacogenomics: Identification of New Drug Targets
57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57


